Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-04-09
1999-12-07
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514284, A61K 3800, A61K 3144
Patent
active
059983779
ABSTRACT:
A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.
REFERENCES:
Gonzalea-Barcena et al., Proc. Int. Cancer Congr., 16th, vol. 3, 2201-2204 Abstract Only, 1994.
Gonzalez-Barcena et al., "Responses to the Antagonistic Analog of LH-RH (SB-75, Cetrorelix) in Patients With Benign Prostatic Hyperplasia and Prostatic Cancer", The Prostate 24, 1994, pp. 84-92.
Oesterling, "Endocrine Therapies for Symptomatic Benign Prostatic Hyperplasia", Supplement to Urology, vol. 43, No. 2, Feb. 1994, pp. 7-16.
B. Lunenfeld, "The Basic Science of GnRH Analogues", Advances in the Study of GnRH Analogues, vol. 2, Nov. 1990, pp. 25-35.
Gormley, GJ, Stoner, E, WO9216233, "Combinations of 5-alpha-reductase inhibitor and antiandrogen--e.g. finasteride and flutamide, for synergistic treatment of protstatic cancer", MERI Mar. 20, 1991.
EP401653A, Boehringer Mannheim GMBH, "Medical Use of Naftopidil--for treating Dysuria Associated With Prostatic Hypertrophy", BOEF Jul. 6, 1989 .
Engel Jurgen
Rawert Jurgen
Reissmann Thomas
Riethmuller-Winzen Hilde
Asta Medica Aktiengesellschaft
Goldberg Jerome D.
LandOfFree
Means for treating prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means for treating prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means for treating prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-823814